1. At a Glance
Welcome to the ₹849 crore IPO parade where Fabtech Technologies Ltd. shows up with sterilized balance sheets, neatly scrubbed EBITDA, and a ₹230.3 crore fresh issue. No OFS drama here, just fresh capital injection — rare sight in today’s promoter exit mela. IPO band: ₹181–191, retail ticket size: ₹14,325 for 75 shares. FY25 revenue clocked ₹336 crore (+46% YoY) with PAT at ₹46.4 crore (+71% YoY). PAT margin? A sweet 13.8%. ROE? A cool 30.5%. For a biopharma engineering company born in 2018, these numbers look like the startup equivalent of Virat Kohli scoring a century on debut.
2. Introduction
Fabtech isn’t your average logistics-truck IPO. These folks design cleanrooms, modular labs, purified water plants, and HVAC systems that pharma/biotech companies literally can’t survive without. Basically: they don’t move your goods; they build the sterile labs where drugs are made so you don’t die from bacteria.
Incorporated in 2018, they’ve grown like college kids on Red Bull — from ₹200 crore revenue in FY23 to ₹336 crore in FY25. Their margins are better than many pharma manufacturers themselves, despite being an engineering project company. IPO timing is chef’s kiss — with global pharma capex rising, India being “pharmacy of the world,” and every country post-COVID wanting its own vials and vaccines.
But here’s the spicy twist: the IPO’s Objects of the Issue statement lists “Funding working capital ₹1,270 crore” — clearly a typo. Either Fabtech is raising ₹230 crore and dreaming of spending ₹1,270 crore (multiverse accounting), or someone cut-paste wrong line. If this is how they handle prospectus drafting, god save the cleanrooms.
3. Business Model – WTF Do They Even Do?
Fabtech calls itself a biopharma engineering turnkey solutions provider. Translation:
- Cleanroom Facilities: Dust-free labs where pharma cos. can make tablets/injections without also manufacturing cockroaches.
- Clean Water Solutions: From 500 to 50,000 LPH purified water systems. Because you can’t make life-saving drugs with Mumbai tap water.
- Clean Air Solutions: HVAC, sterile ventilation for life sciences, semiconductors, food, and even aerospace. Basically, they’re selling expensive, overqualified air conditioners.
- End-to-End Execution: Design → Engineering → Manufacturing → Installation → Project Management. Clients just cut the cheque, Fabtech delivers the sterile Lego set.
Their edge? Global execution experience, diversified clients, and ability
